Navigation Links
Gentris Corporation Opens New Genomic Biomarker Laboratory in China
Date:11/20/2013

MORRISVILLE, N.C., Nov. 20, 2013 /PRNewswire/ -- Gentris® Corporation (www.gentris.com), a global leader in the application of genomic biomarkers to clinical studies, announced today that it has opened a new genomic biomarker testing and biorepository services laboratory in Shanghai, China. Gentris Shanghai will provide GCLP-compliant testing and biobanking services for global pharmaceutical clients under international standards.

(Logo: http://photos.prnewswire.com/prnh/20130916/CL80771LOGO )

"The launch of Gentris Shanghai is a tremendous milestone for our company," said Dr. Amelia Wall Warner, Gentris President and CEO. "Gentris is creating an international quality, global organization capable of providing genomic biomarker testing and biobanking services for clinical trials. In addition to commercial services, we are building collaborations with top Chinese research organizations, universities, and companies to accelerate drug development and innovation."

Gentris Shanghai will solve a critical need for pharmacogenomic (PGx) testing and clinical sample storage under international standards in China. Drug developers increasingly conduct large, integrated clinical trials that span the globe. China has been a primary focus in recent years due to a rapidly growing economy and tremendous investments in pharmaceutical, biotechnology, and innovation infrastructure. Gentris Shanghai provides the necessary services and expertise to conduct PGx-enabled clinical trials in China and accelerate drug development globally.

"This is an exciting time for Gentris as we expand into China, which is now the third largest pharmaceutical market in the world," said Dr. Tong Zhou, Gentris Shanghai General Manager. "Our sponsors are increasingly incorporating China into global clinical trials and we are working with them to meet a critical need for harmonized, international standards for biobanking and genomic biomarker testing."

Initial services will include biobanking and nucleic acid prep. Genotyping and gene expression services will launch in 2014 with phased implementation based on market demand.

Gentris Shanghai is also working closely with government organizations, medical researchers, and hospitals to create translational research, education, and training collaborations focused on genomic biomarker testing and biobanking that will drive innovation in drug development and patient care. For example, Gentris, the Shanghai Institutes of Preventative Medicine, and an independent research institute are conducting a study to collect and analyze biospecimens from tuberculosis patients in China to evaluate drug-induced liver injury and potential biomarkers. By working with Gentris and its collaborators, industry sponsors will be able to gain access to unique clinical samples, patient populations, and new technology in China.

Related Links: www.gentris.com

About Gentris Corporation:
Founded in 2001, Gentris is located in Research Triangle Park, NC, where it provides pharmacogenomics and biorepository support for all phases of clinical studies and genomic biomarker programs. The company works with academic and industry leaders to translate innovations in pharmacogenomics into safer, more effective medicines, which can lead to accelerated drug development and improvement in patient care globally. In the past year, Gentris has significantly expanded its facility and onsite biorepository to meet the increased needs of biopharma clients, while maintaining a preeminent quality system.

About Gentris Shanghai
Gentris Shanghai builds on over 10 years of genomic biomarker testing and biorepository services in the USA. The company was created from the ground up to ensure the highest quality services performed under international regulatory standards. The mission of Gentris Shanghai is to enable globally-integrated pharmacogenomics drug development studies in China. In addition to commercial services, Gentris Shanghai has built relationships with leading research organizations, hospitals, universities, and government agencies in China in order to facilitate collaborations and partnerships that can accelerate innovation and improve patient care globally.


'/>"/>
SOURCE Gentris Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Gentris Corporation Partners with the Shanghai Institutes of Preventative Medicine
2. Gentris Corporation Launches New Pharmacogenomics Services
3. Gentris Corporation Announces Collaboration to Study Blood Stability
4. Gentris Corporation Expands Headquarters, Biorepository
5. Gentris Integrated Biorepository Receives Accreditation From The College of American Pathologists
6. Gentris Corporation Launches Next Generation Human Transcriptome Array
7. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
8. CVS Caremark Corporation to Hold First Quarter 2012 Conference Call
9. Richard Wolf Medical Instruments Corporation: 40 Years of Innovation
10. Haemonetics Signs Definitive Agreement to Acquire Pall Corporations Blood Collection, Filtration and Processing Product Lines For $551 Million
11. Luminex Corporation Reports First Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... Dec. 2, 2016 CVS Health Corporation (NYSE: ... Day in New York City on Thursday, December 15, 2016, beginning at 8:00 ... team will provide an in-depth review of the company,s ... The company will also discuss 2017 earnings guidance during ... of the event will be broadcast simultaneously on the ...
(Date:12/2/2016)... 2, 2016 Lianluo Smart Limited (Nasdaq: ... Company") which develops, markets and sells medical devices ... China and international markets, recently attended ... Treatment New Progress Forum, co-hosted by the Institute ... , Guangdong Provincial People,s Hospital and Cardiology ...
(Date:12/2/2016)... , December 2, 2016 On ... down 1.36%; the Dow Jones Industrial Average edged 0.36% higher, ... 2,191.08, down 0.35%. Losses were broad based as six out ... has initiated research reports on the following Services equities: Myriad ... QGEN ), INC Research Holdings Inc. (NASDAQ: ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... ... With the number of pain management programs available for people suffering with constant ... works for them. When an inventor from Suisun City, Calif., was unsuccessful in finding ... it with others. , He developed a prototype for PRO GO MASSAGE to relieve ...
(Date:12/2/2016)... ... December 02, 2016 , ... CloudLIMS.com, a class-leading provider of ... Lite. CloudLIMS Lite helps biobanks, clinical, research and testing laboratories keep track of ... new version is a faster and a more efficient product, allowing batch processing ...
(Date:12/2/2016)... ... 2016 , ... Yisrayl Hawkins, at The House of Yahweh in Abilene, Texas, ... Bible Prophecy. Yisrayl says this generation, known as the Last Generation, started in 1934 ... details line up exactly with Bible Prophecy – a protected way for those who ...
(Date:12/2/2016)... ... December 02, 2016 , ... Date aired: November 28, ... 2 Diabetes: The Owner’s Manual, http://realtimepressrelease.com/press-releases-tagged-with/daryl-wein , Sharon Kleyne, America’s ... Global Climate Change and Your Health radio program syndicated on Voice of America, ...
(Date:11/30/2016)... Wisconsin (PRWEB) , ... November 30, 2016 , ... ... in the 2016 Deloitte Wisconsin 75, an annual ranking and recognition of the ... year on the list, having ranked from 2008-2016. In addition, Standard Process was ...
Breaking Medicine News(10 mins):